Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 2Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 18Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Follicular 5Recurrence 4Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma 3Waldenstrom Macroglobulinemia 2Neoplasms, Plasma Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Leukemia 2Sezary Syndrome 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Neoplasm, Residual 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Immunoblastic 1Leukemia, Plasma Cell 1Leukemia, Hairy Cell 1Intraocular Lymphoma 1Hematologic Neoplasms 1Hematologic Diseases 1Burkitt Lymphoma 1Blood Protein Disorders 1

Interventions

Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Blood Protein Disorders × Lenalidomide × Clear all
NCT02155634 2018-04-10

Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma

Celgene

Phase 3 Withdrawn
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡